Similar articles

• Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility.

  Wolff TA, Wilson JE. Wolff TA, et al. Am Fam Physician. 2006 Nov 15;74(10):1759-60. Am Fam Physician. 2006. PMID: 17137007 Review. No abstract available.
• Optimal selection of individuals for BRCA mutation testing: a comparison of available methods.

  James PA, Doherty R, Harris M, Mukesh BN, Milner A, Young MA, Scott C. James PA, et al. J Clin Oncol. 2006 Feb 1;24(4):707-15. doi: 10.1200/JCO.2005.01.9737. J Clin Oncol. 2006. PMID: 16446345
• Does the search for large genomic rearrangements impact BRCAPRO carrier prediction?

  Capalbo C, Buffone A, Vestri A, Ricevuto E, Rinaldi C, Zani M, Ferraro S, Frati L, Screpanti I, Gulino A, Giannini G. Capalbo C, et al. J Clin Oncol. 2007 Jun 20;25(18):2632-4; author reply 2634-5. doi: 10.1200/JCO.2007.11.4330. J Clin Oncol. 2007. PMID: 17577048 No abstract available.
• Mutations of BRCA genes in hereditary breast and ovarian cancer.

  Radice P. Radice P. J Exp Clin Cancer Res. 2002 Sep;21(3 Suppl):9-12. J Exp Clin Cancer Res. 2002. PMID: 12585647 Review.
• Towards more effective and equitable genetic testing for BRCA1 and BRCA2 mutation carriers.

  James PA, Harris M, Lindeman GJ, Mitchell G. James PA, et al. J Med Genet. 2008 Nov;45(11):765-6. doi: 10.1136/jmg.2008.061903. J Med Genet. 2008. PMID: 18978334 No abstract available.